VTYX
FY2029 EPS Estimate
$0.09
FY2029E EPS$0.09

Analyst Sentiment

Wall St. Consensus
Hold
11 analysts·Moderate coverage
59
Score
4 Buy (36%)7 Hold (64%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
436%
Hold
764%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$14.00
+0.0%
Consensus
$14.00
+0.0%
Bull
$60.00
+328.6%
12-Month Target Range11 analysts
$14.00$14.00$60.00
Current $14.00Consensus
Current Price
$14.00
Upside to Consensus
$0.00

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+133.36%
EPS
FY2028
Rev+774.26%
EPS
FY2029
Rev+47.61%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$13M$31M$267M$394M
Low$13M$31M$267M$394M
High$13M$31M$267M$394M
EBITDA Avg$-116M$-145M$-12M$8M
Low$-131M$-155M$-90M$8M
High$-101M$-77M$85M$8M
EBIT Avg$-117M$-145M$-12M$8M
Low$-132M$-156M$-91M$8M
High$-102M$-78M$84M$8M
Net Income Avg$-117M$-145M$-12M$6M
Low$-132M$-156M$-91M$6M
High$-102M$-78M$66M$6M
EPS Avg$-1.77$-1.60$-0.55$0.09
Low$-1.92$-2.27$-1.32$0.09
High$-1.49$-1.14$0.97$0.09
Analysts (Rev / EPS)6 / 55 / 65 / 52 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$13M$33M
Low$13M$33M
High$13M$33M
EBITDA Avg$-36M$-35M
Low$-36M$-35M
High$-36M$-35M
EBIT Avg$-36M$-35M
Low$-36M$-35M
High$-36M$-35M
Net Income Avg$-36M$-35M
Low$-36M$-35M
High$-36M$-35M
EPS Avg$-0.50$-0.50
Low$-0.50$-0.50
High$-0.50$-0.50
Analysts (Rev / EPS)1 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Jan 8, 2026Piper Sandler
Ventyx Biosciences downgraded to Neutral from Overweight at Piper Sandler
Target:$14.00
+1.6%from $13.79
Jan 8, 2026H.C. Wainwright
Ventyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright
Target:$14.00
+2.0%from $13.73
Jan 8, 2026UBS
Ventyx Biosciences downgraded to Neutral from Buy at UBS
Target:$14.00
+2.0%from $13.73
Jan 8, 2026Canaccord Genuity
Ventyx Biosciences downgraded to Hold from Buy at Canaccord
Target:$14.00
+2.0%from $13.73
Jan 7, 2026UBS
Ventyx Biosciences initiated with a Buy at UBS
Target:$20.00
+45.1%from $13.78
Nov 5, 2025H.C. Wainwright
Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wainwright
Target:$18.00
+122.5%from $8.09
Oct 27, 2025Oppenheimer
Ventyx Biosciences price target raised to $14 from $9 at Oppenheimer
Target:$14.00
+136.2%from $5.93
Jun 13, 2024H.C. Wainwright
H.C. Wainwright Maintains Ventyx Biosciences (VTYX) at Neutral, NT-0796 results have "limited significance"
Target:$6.00
+101.3%from $2.98
Jun 6, 2024Oppenheimer
Ventyx Biosciences Inc (VTYX) PT Lowered to $10 at Oppenheimer
Target:$10.00
+89.4%from $5.28
Mar 12, 2024Wells Fargo
Wells Fargo Upgrades Ventyx Biosciences Inc (VTYX) to Overweight, 'We're Taking a Swing on VTYX's NLRP3 Programs'
Target:$16.00
+90.0%from $8.42
Mar 12, 2024Oppenheimer
Oppenheimer Upgrades Ventyx Biosciences Inc (VTYX) to Outperform, 'Narrows Focus to the NLRP3 Programs'
Target:$12.00
+42.5%from $8.42
Dec 19, 2022Goldman Sachs
Goldman Sachs Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $50
Target:$50.00
+53.2%from $32.64
Nov 17, 2022Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
Target:$45.00
+77.0%from $25.43
Sep 13, 2022Jefferies
Ventyx Biosciences (VTYX) Stock: Why It Surged 64.98%
Target:$60.00
+57.4%from $38.11
May 12, 2022Piper Sandler
Ventyx Biosciences 'top pick' heading into data-rich Q3, says Piper Sandler
Target:$50.00
+244.1%from $14.53
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.